This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m.

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

The Columbia County Spring Fair is back in town, but this time with some policy changes amid disruptions last week.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...